Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,122.00
Bid: 12,118.00
Ask: 12,122.00
Change: -34.00 (-0.28%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

1 Dec 2021 15:00

RNS Number : 2427U
AstraZeneca PLC
01 December 2021
 

1 December 2021 15:00 GMT

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

 

Date: 1 December 2021

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 JUNE 2021

To:

30 NOVEMBER 2021

Balance of unallotted securities under scheme(s) from previous return:

5,252,778

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

65,397

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,187,381

 

Name of contact:

Hannah Tattersall

Telephone number of contact:

+44 (0)746 498 2582

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFSLFEFEFSEEE
Date   Source Headline
3rd Oct 20237:00 amRNSAstraZeneca settles Nexium liability litigations
2nd Oct 20233:00 pmRNSTotal Voting Rights
22nd Sep 20237:00 amRNSDato-DXd improved PFS in breast cancer
20th Sep 20237:00 amRNSAlexion completes Pfizer gene therapy agreement
15th Sep 20233:00 pmRNSEnhertu recommended in EU for HER2-mutant NSCLC
11th Sep 20234:00 pmRNSFasenra Phase III EGPA trial met primary endpoint
6th Sep 20237:00 amRNSUpdate on US review of Ultomiris for NMOSD
1st Sep 20233:00 pmRNSTotal Voting Rights
1st Aug 20233:00 pmRNSTotal Voting Rights
28th Jul 20237:05 amRNSAlexion enters gene therapy agreement with Pfizer
28th Jul 20237:00 amRNSHalf-year Report
17th Jul 20236:10 pmRNSBeyfortus approved in US for infant RSV prevention
3rd Jul 20233:00 pmRNSTotal Voting Rights
3rd Jul 20237:00 amRNSDato-DXd significantly improved PFS in lung cancer
9th Jun 20237:05 amRNSnirsevimab recommended for infant RSV protection
9th Jun 20237:00 amRNSAstraZeneca agreement with Quell Therapeutics
2nd Jun 20235:00 pmRNSImfinzi improved pCR in gastric and GEJ cancers
1st Jun 20233:05 pmRNSBlock listing Interim Review
1st Jun 20233:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSLynparza approved in US for BRCAm prostate cancer
26th May 20237:00 amRNSImfinzi + Lynparza prolonged PFS in endometrial ca
22nd May 20237:05 amRNSDirectorate Change
17th May 20237:00 amRNSTagrisso plus chemo improved PFS in lung cancer
9th May 202311:00 amRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSFarxiga extended in the US for heart failure
2nd May 20233:00 pmRNSTotal Voting Rights
2nd May 202310:00 amRNSDirector/PDMR Shareholding
2nd May 20237:00 amRNSODAC vote on Lynparza combo in prostate cancer
27th Apr 20235:30 pmRNSResult of AGM
27th Apr 20237:05 amRNSBoard Committee Changes
27th Apr 20237:00 amRNS1st Quarter Results
26th Apr 20234:45 pmRNSDirector Declaration
11th Apr 20237:00 amRNSUpdate to arrangements with Sobi and Sanofi
5th Apr 20237:00 amRNSLynparza + Imfinzi met endpoint in ovarian cancer
3rd Apr 20233:00 pmRNSTotal Voting Rights
3rd Apr 20237:00 amRNSUltomiris recommended for NMOSD EU approval
30th Mar 20237:00 amRNSAstraZeneca completes KYM agreement for CMG901
27th Mar 202311:00 amRNSDirector/PDMR Shareholding
22nd Mar 202311:00 amRNSNotice of AGM
9th Mar 20237:00 amRNSImfinzi improved EFS in resectable lung cancer
8th Mar 202311:01 amRNSDirector/PDMR Shareholding
8th Mar 202311:00 amRNSDirector/PDMR Shareholding
6th Mar 20237:00 amRNSEnhertu DESTINY-PanTumor02 shows positive results
1st Mar 20233:00 pmRNSTotal Voting Rights
1st Mar 20237:00 amRNSAstraZeneca prices a $2.25bn bond offering
24th Feb 20236:15 pmRNSAstraZeneca prices a EUR1.5bn bond offering
24th Feb 20232:05 pmRNSAstraZeneca acquires CinCor for cardiorenal asset
24th Feb 202311:00 amRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSAstraZeneca enters agreement with KYM for CMG901
22nd Feb 20237:10 amRNSFiling of Form 20-F with SEC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.